Trastuzumab News and Research

RSS

Study maps HER2 mutations in lung cancer patients from Northeastern Brazil

A new research paper was published in Volume 16 of Oncotarget on June 17, 2025, titled "Molecular landscape of HER2-mutated non-small cell lung cancer in Northeastern Brazil: Clinical, histopathological, and genomic insights."

27 Jun 2025

THP regimen achieves high response rates in HER2 positive breast cancer patients

Patients with Stage II and III (early-stage) HER2+ breast cancer usually undergo pre-operative therapy with multi-agent chemotherapy in combination with anti-HER2 antibodies, followed by surgery.

2 Jun 2025

Targeted drug zongertinib shows strong results for HER2-mutant lung cancer in clinical trial

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced HER2-mutant non-small cell lung cancer – particularly those with specific HER2 mutations – with manageable side effects, according to results from the Phase Ia/Ib Beamion LUNG-1 trial led by researchers from The University of Texas MD Anderson Cancer Center.

28 Apr 2025

Breast cancer deaths expected to fall in the EU and UK by 2025 across most age groups

Death rates from breast cancer will fall in 2025 in every age group in the EU and the UK apart from in EU patients aged 80 years and older. In these older patients, overall mortality rates from the disease are predicted to rise by nearly 10% in 2025.

12 Mar 2025

2024 CSCO Breast Cancer guidelines revolutionize treatment approaches in China

Breast cancer remains a major global health challenge, with treatment strategies varying widely across regions.

14 Feb 2025

Genomic insights and new treatment paradigms related to HER2-low breast cancer

A new review was published in Oncotarget's Volume 16 on January 20, 2025, titled "Evolving concepts in HER2-low breast cancer: Genomic insights, definitions, and treatment paradigms."

22 Jan 2025

T-DM1 reduces long-term risk of death in HER2-positive breast cancer patients

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and improved survival compared to trastuzumab alone, according to the final results of the phase 3 KATHERINE clinical trial led by researchers from the University of Pittsburgh and UPMC Hillman Cancer Center.

16 Jan 2025

A new era of targeted therapy with antibody–drug conjugates

TBC

From Sino Biological Inc. 16 Dec 2024

PATINA trial demonstrates benefit of palbociclib in HR+ HER2+ metastatic breast cancer

Alliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating that the addition of palbociclib (IBRANCE) to current standard-of-care first-line maintenance therapy (following induction chemotherapy) resulted in statistically significant and clinically meaningful improvement in progression-free survival (PFS) by investigator assessment in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC).

12 Dec 2024

New blood test detects early lung damage in cancer patients on targeted therapy

New study introduces a simple blood test to detect early lung damage in cancer patients receiving novel therapy with antibody-drug conjugates (ADCs), which can sometimes cause serious, even fatal, lung disease (ILD).

12 Nov 2024

Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care

The 2024 National Foundation for Cancer Research (NFCR) Global Summit and Award Ceremonies for Cancer Research & Entrepreneurship, co-hosted with the AIM-HI Accelerator Fund, convened the world's top experts across cancer research, biotech entrepreneurship, pharmaceuticals, investment, and patient advocacy.

28 Oct 2024

HER2-postive breast cancer drugs show promise for bile duct cancer treatment

Drugs designed to target HER2-postive breast cancer could also benefit some patients with bile duct cancer, according to results of a patient trial to be presented on Thursday at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.

23 Oct 2024